Press Releases - 2020-06-13

Date	Title	Company
13-Jun-2020	Growth in Gene Synthesis, Bioinformatics Technology to Boost Synthetic Biology Market	markets and markets
13-Jun-2020	New Late-Breaking Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1C Levels in People with Type 2 Diabetes Using Insulin or Not	Abbott
13-Jun-2020	New Late-Breaking Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1C Levels in People with Type 2 Diabetes Using Insulin or Not	Abbott
13-Jun-2020	Switching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice	Novo Nordisk
13-Jun-2020	Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress	Halozyme Therapeutics, Inc.
13-Jun-2020	Designer Biosensors to Probe the Activation of Important Drug Targets - Research by Prof Arun Shukla, Department of BSBE, IIT Kanpur	Indian Institute Of Technology Kanpur
13-Jun-2020	Subcutaneous Formulation of DARZALEX®▼(Daratumumab) Combination Resulted in Deep and Rapid Haematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis	Janssen Pharmaceutical Companies of Johnson & Johnson
13-Jun-2020	EHA25Virtual: A Paradigm Shift for the Treatment of Newly Diagnosed Older Acute Myeloid Leukemia Patients	European Hematology Association (EHA)
13-Jun-2020	EHA25Virtual: A Paradigm Shift for the Treatment of Newly Diagnosed Older Acute Myeloid Leukemia Patients	European Hematology Association (EHA)
13-Jun-2020	EHA25Virtual: Study of Subcutaneous Daratumumab Shows Improved Clinical Outcomes in the Treatment of Patients with Amyloidosis	European Hematology Association (EHA)
13-Jun-2020	EHA25Virtual: Study of Subcutaneous Daratumumab Shows Improved Clinical Outcomes in the Treatment of Patients with Amyloidosis	European Hematology Association (EHA)
13-Jun-2020	VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients	AbbVie
13-Jun-2020	VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients	AbbVie
13-Jun-2020	Physio Omega Reviews – Is it the Ultimate Solution to a Healthy Heart?	Wired Release
13-Jun-2020	Braskem's 2019 Form 20-F Was Filed	Braskem S.A.